Robert W Duggan

Summit Therapeutics Co-CEO Duggan buys 3,810,000 shares ($50.0M) at $13.12; stock down -56.6% from 52-week high, cluster buy pattern detected

Robert W Duggan purchased 3,810,000 shares at $13.12 on 2026-06-12, adding $50.0M to a position that now totals 573.88M shares. The purchase occurs in a sharp decline context: the stock is trading -56.6% from its 52-week high of $30.98 and down -28.4% over the past 30 days. At SMMT specifically, Duggan's prior 3 measurable trades have delivered mixed results—a recent 30-day win (20.8%) reversed into a 90-day loss (-3.7%), and a -12.2% 30-day loss extended to -9.1% at 90 days—with none of the prior trades being well-timed at the 90-day mark. The company is reporting zero revenue in the latest quarter and is unprofitable, with full-year net income at negative $189.4M. A cluster pattern is present: two other insiders also bought within the past 14 days, suggesting coordinated conviction at depressed prices. This filing merits scrutiny given the timing into a severe drawdown, the company's negative fundamentals, and Duggan's uneven track record at this specific ticker.

Robert W Duggan (Co-CEO) buys 100,000 shares of SMMT at $14.60; stock now -52.1% from 52-week high, cluster buy pattern detected.

Co-Chief Executive Officer Robert W Duggan purchased 100,000 shares at $14.60 on 2026-06-04, increasing holdings to 25.82M shares. The transaction occurred as the stock trades 52.1% below its 52-week high of $30.98 and has fallen 15.4% over the prior 30 days. At this same ticker, Duggan's 3 prior buys have shown poor timing at the 90-day mark: 0 of 3 prior purchases were well-timed, with results ranging from -12.2% to +20.8% at 30 days but consistently negative at 90 days. Two other insiders also purchased shares within the past 14 days, indicating a cluster-buy pattern. The company remains unprofitable with net income of $-189.4M over the most recent full fiscal year, though Duggan's cross-ticker track record shows an average 90-day return of +3.9% across 20 prior buys, with a 40.00% win rate.

Director and 10% owner Robert Duggan purchases $13M in PLSE shares as stock trades below 52-week highs; 26th open-market buy in 36 months.

Robert Duggan, a director and major shareholder, has committed roughly $13 million to acquire shares at prices between the 52-week low and current levels, expanding his position significantly. This represents his 26th open-market purchase over the past three years—an unbroken pattern of accumulation with no offsetting sales. Duggan's prior purchases at this company have produced mixed near-term results (four of his previous five buys saw initial gains, but all five trades ultimately declined over a longer timeframe), suggesting his timing has been inconsistent. The company itself remains unprofitable with substantial operating losses, though it is generating meaningful revenue, meaning Duggan is buying a loss-making biotech business at a point when the stock sits notably below its 52-week highs. The scale and consistency of his purchasing activity—combined with his director status and substantial ownership stake—distinguishes this from routine insider trades, though his historical track record of poor long-term outcomes after prior purchases at this same company tempers the signal.

Co-CEO Duggan buys 26,680 shares at $18.74 for $500.0K, increasing SMMT holdings 53.4%; cluster of 3 insider buys in 14 days amid -34.6% 90-day decline and $-231.8M annual loss.

Robert W. Duggan, Co-Chief Executive Officer, purchased 26,680 shares at $18.74 on 2025-10-21, increasing his total holdings to 76,680 shares (a 53.4% increase from pre-transaction holdings). The purchase occurred as the stock is down 34.6% over 90 days and trades 48.9% below its 52-week high of $36.70. This transaction is part of a cluster pattern: 2 other insiders also bought within the past 14 days. Duggan's prior two purchases at SMMT on 2025-09-10 and 2025-09-11 each showed positive 30-day performance (+20.8% and +18.2% respectively), though 90-day outcomes are not yet measurable. Notably, the company is unprofitable, having reported net income of $-231.8M in its most recent full fiscal year, which adds material context to why the timing and clustering of these insider purchases warrants investor scrutiny of the strategic rationale.

Director Duggan buys 192,599 shares for $2.8M at $14.48 avg across 3 trades; stock -40.9% from 52-week high.

Robert W. Duggan, Director at PULSE BIOSCIENCES, completed 3 separate purchases totaling 192,599 shares for $2,788,624.34 between September 10–12, 2024, at prices ranging from $14.41 to $14.77. His post-transaction holdings of 47.71M shares represent a modest 0.4% increase. The current market price of $14.52 sits -40.9% below the 52-week high of $24.56, and the stock has declined -13.5% over the past 30 days. Duggan's same-ticker history shows 5 prior buys at PLSE with mixed timing outcomes; 3 of 5 achieved positive 90-day returns, whereas his cross-ticker track record displays an 81.25% 90-day win rate with an average 90d return of +11.9%. The company reported $0.00 revenue in the latest quarter and a $-19.2M net loss, indicating ongoing unprofitability. The transaction signals insider accumulation during a period of material stock decline, but the modest portfolio impact and company's unprofitable state warrant careful monitoring of subsequent developments.

Co-CEO Duggan buys 338.4K shares for $6.0M at $17.69 avg amid 49.3% stock decline from 52-week high

Robert W. Duggan, Co-Chief Executive Officer, executed 2 separate purchases totaling 338.4K shares for $6.0M on September 10-11, 2025, at a blended average price of $17.69 per share. This occurs while the stock trades at $18.60, down 49.3% from its 52-week high of $36.70 and down 27.6% over the preceding 30 days, representing a period of significant share price deterioration. The company is unprofitable with a net income of -$565.7M in its latest fiscal year and zero revenue in the latest quarter, indicating material operational challenges. Duggan's cross-ticker track record shows 20 prior open-market buys with an 82.35% 90-day win rate and average 90-day return of +10.2%, establishing a pattern of execution discipline; however, this company-specific context—deep losses, zero revenue, and a severely depressed valuation after multi-month declines—is substantially different from the broader portfolio metrics and demands separate scrutiny.

Director Robert Duggan buys 45,404 shares of PLES at $17.13 despite company burning cash with -$12.7M net income and -100% revenue growth

Director Robert Duggan purchased 45,404 shares at $17.13 for $777,770.52, adding to his substantial 42.27M share position. Notably, this purchase occurs in a context where Pulse Biosciences reported zero quarterly revenue and a full-year net loss of -$12,680,000, with annual revenue declining by -100.0%. While Duggan's cross-ticker track record shows strong execution (93.75% 90-day win rate, avg 90d return +17.2% across 20 prior buys), this metric reflects performance across other securities, not necessarily this specific company's trajectory. The purchase represents only a +0.1% increase to his existing 42.23M holdings, a relatively modest addition given the scale of his current position. The transaction demands scrutiny as to whether it reflects contrarian conviction in a cash-burn scenario, portfolio maintenance of existing exposure, or other strategic intent—distinctions that current filings do not clarify.

Director Robert W Duggan buys 55,256 shares of PLSE at $17.18; cross-ticker track record shows 93.75% 90d win rate, yet company posts -$12.7M net income with -100% revenue growth.

Robert W Duggan, a director, purchased 55,256 shares at $17.18 on 2024-12-13, adding to his 42.33M-share position. Across his 20 prior open-market buys at other tickers, Duggan has achieved a 93.75% 90-day win rate with avg 90d return of +17.2%. At PLSE specifically, his 3 measurable prior buys have all shown positive 90-day returns (ranging +12.9% to +19.8%), establishing a pattern of well-timed entry points at this ticker. However, PULSE Biosciences itself is in financial distress: latest quarter revenue is $0.00, full-year net income was -$12.7M, and annual revenue growth is -100.0%. While his prior purchase timing on this stock has been accurate, the company's deteriorating fundamentals—shifting from revenue to zero in the latest quarter—represent a material headwind that complicates the traditional interpretation of an insider buy signal.

Director Robert W Duggan purchased 56,054 shares at blended average $17.35 on 2024-12-11, extending pattern of well-timed buys at PLSE despite -$12.7M net income.

Director Duggan executed 2 purchases totaling 56,054 shares for $972,343.96 at an average price of $17.35, increasing his holdings from 42.17M to 42.23M shares. His prior trades at PLSE show a 4 of 4 pattern of well-timed buys (all returned +12.9% to +19.8% over 90 days), consistent with his cross-ticker track record of 94.12% win rate on buys with average 90d return +16.7%. However, the company reported $0.00 revenue in the latest quarter, -$12.7M net income, and -100.0% annual revenue growth, indicating sustained operating losses and no revenue generation. The timing of this purchase at $17.35—19.2% below the 52-week high of $21.83 but 1.5% higher over the 30-day window—occurs in a context of negative fundamentals and operational challenges that distinguish this from pure valuation-driven accumulation.